This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Johnson & Johnson Pharmaceuticals Segment Poised To Continue Driving Growth With More Than 10 Potential New Product Filings By 2017

NEW BRUNSWICK, N.J., May 23, 2013 /PRNewswire/ -- At a meeting today with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced they anticipate submitting more than 10 new product filings and more than 25 significant brand line extensions by 2017.

To view the multimedia assets associated with this release, please click:

With a unique model of innovation, the Pharmaceuticals segment of Johnson & Johnson (NYSE: JNJ) has built an industry-leading pipeline that has yielded 11 new product launches since 2009, more than doubling its productivity over the past four years.  These new products, coupled with core growth brands, have fueled 12 consecutive quarters of operational sales growth in the segment and contributed significantly to the Company's recent earnings growth.

"Our investment in transformational innovation has enabled strong growth that has allowed us to continue investing in our future portfolio," said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson, and Worldwide Chairman, Pharmaceuticals Group.  "With a steadfast focus on the most serious unmet medical needs, our approach is to identify the best science — internal and external — to deliver new options and solutions to patients.  Today, we have an industry-leading pipeline of truly differentiated products and a track record of success resulting in more new molecular entity (NME) approvals per year at a lower development cost than the industry average."

"We've spent the past five years transforming our business, and the growth we're seeing today is the direct impact of that effort," said Joaquin Duato, Worldwide Chairman, Pharmaceuticals Group.  "The innovative new therapies in our pipeline will drive our next wave of growth.  With strong momentum across our global Pharmaceuticals segment, we are executing well against our commercial strategy to gain market share and ensure greater access to our medicines.  We're also strengthening our presence in critical geographies and have nearly doubled our footprint in emerging markets during the last five years."

The total global pharmaceuticals market is expected to grow about 4.5% annually and reach an approximate market size of $1.2 trillion by 2017, according to IMS Health, the independent analysis and market research service that tracks the industry.  Among the top 10 global pharmaceutical companies, IMS Health also reports that the Pharmaceuticals business of Johnson & Johnson was the fastest growing in the U.S., Europe and Japan in 2012, with sales of $25.4 billion, an operational * increase of nearly 7% versus 2011.  Strong sales growth in the segment continued in the first quarter of 2013, with worldwide sales of $6.8 billion, an operational * increase of over 11% versus the prior year.  Emerging markets, including China, Brazil, Russia and India, comprised nearly 20% of worldwide pharmaceutical sales in the first quarter of 2013.

"We're proud to be one of the most productive pharmaceutical organizations in the world, with a portfolio that includes many 'firsts,' representing meaningful innovations that create significant benefits for patients, enhanced access to markets, and value for shareholders," said William Hait, M.D., Ph.D., Global Head, Janssen Research & Development, LLC.  "We are working to sustain our cycle of success into the next decade and beyond by leveraging the scientific expertise we've built in our core disease areas to identify the best science and deliver innovative solutions for patients."

The Company's approach to innovation has resulted in a revitalized product portfolio for the Janssen Pharmaceutical Companies of near- and long-term compounds in the areas of Immunology, Neuroscience, Infectious Diseases and Vaccines, Cardiovascular and Metabolism, and Oncology.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 -1.04%
FB $118.06 0.54%
GOOG $695.70 0.48%
TSLA $222.56 -4.20%
YHOO $36.00 -0.03%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs